Forum Topic News
  • Conversation: Indivior push to diversify boosted by schizophrenia drug approval

    • July 31, 2018 1:51 PM BST
    • Indivior push to diversify boosted by schizophrenia drug approval

      For years, Indivior has made the bulk of its revenues from opioid addiction treatment Suboxone. Now, it’s taken a step towards reducing its reliance on that cash cow, which is under pressure from generic competition.
      The UK drugmaker has just won FDA approval for Perseris, a monthly injectable formulation of atypical antipsychotic risperidone, to treat schizophrenia.
      It will launch in competition to other monthly therapies, such as Lundbeck/Otsuka’s market leading Abilify Maintena (aripiprazole) and Johnson & Johnson’s Invega Sustenna (paliperidone) but, for now, Indivior isn’t predicting when that will take place. In a press release, the company says its launch – originally slated for the fourth quarter – will now be reviewed in light of a recent court decision relating to Suboxone (buprenorphine/naloxone) in the US.
      Read more: http://www.pmlive.com/pharma_news/indivior_push_to_diversify_boosted_by_schizophrenia_drug_approval_1246373

Add Reputation

Do you want to add reputation for this member by this post?

or cancel